Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a bone drug stop brain damage in rare Fahr's disease?

NCT ID NCT05662111

First seen Mar 09, 2026 · Last updated May 22, 2026 · Updated 9 times

Summary

This study tests whether etidronate, a drug used for bone disorders, can slow or stop calcium buildup in the brain that causes Fahr's disease. The trial will enroll 98 adults with Fahr's disease or syndrome. Participants will receive either etidronate or a placebo for a year to see if the drug improves thinking, movement, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAHR DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University College London Hospital

    NOT_YET_RECRUITING

    London, United Kingdom

    Contact

    Contact Phone: •••-•••-••••

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, Utrecht, 3584 CX, Netherlands

    Contact

Conditions

Explore the condition pages connected to this study.